From 512,000 euros in 2013, it rose to over 6 million forfeited in 2014. In Italy, "Sovaldi" is accessible to a limited number of patients, about 30,000 out of a population of healthy carriers estimated at around one and a half million. But still in Italy, distribution is slow, while in San Marino it has been available for purchase since it received the go-ahead in America.
Of Michele Macina published on Saturday 21 February 2015 – Libertas
Franco Cavalli – San Marino Today
Leading the ranking are new medicines for the treatment of Hepatitis C which are struggling to be available in Italy due to high costs / The ISS multiplies the receipts by 6 thanks to the drugs sold to Italians / From 512,000 euros in 2013 we have moved on to over 6 million forfeited in 2014
The cure for hepatitis C? Italians buy it in San Marino. The drug is called "Sovaldi" and is a new medicine against hepatitis C approved in 2013 in the United States, where it boasts a certification of efficacy of over 90% of healings. In Italy, the approval of the patent arrived in 2014 and the National Health Service reached an agreement with the company that produces it - Gilead - which resulted in a cost of 600 euros for each single tablet and therefore of an expense between 40 and 60 thousand euros for the entire therapy. "Sovaldi" is therefore a very expensive drug, so much so that the National Health Service has established that a limited number of patients can access it, about 30 thousand out of a population of healthy carriers estimated at around one and a half million. But still in Italy, distribution is slow, while in San Marino it has been purchasable since it got the go-ahead in America.
Out of the 49 products (including drugs and over-the-counter medicines) that produce the highest collections, the top five in the standings are all sold to foreign citizens, in practice almost all to Italians. In total, in the ranking of the 49 most profitable, there are 18 drugs sold to foreign countries and in 2014 they produced revenues of 3,047,503.87 euros out of a total of 7,156,375.12 euros
